Gene Expression Signature of Chemoresistance in Gastric Cancer
Author Information
Author(s): Kim Hark Kyun, Choi Il Ju, Kim Chan Gyoo, Kim Hee Sung, Oshima Akira, Michalowski Aleksandra, Green Jeffrey E.
Primary Institution: National Cancer Institute
Hypothesis
Can we identify transcriptional alterations associated with acquired chemotherapy resistance in gastric cancer patients?
Conclusion
The identified gene expression signature may help predict which gastric cancer patients will respond to chemotherapy and guide treatment decisions.
Supporting Evidence
- The study identified a 633-gene signature that predicts time to progression after chemotherapy.
- Patients with higher expression of the acquired resistance signature had significantly shorter time to progression.
- The signature was enriched for genes associated with the mTOR pathway, which is linked to chemotherapy resistance.
Takeaway
This study found a special pattern in the genes of stomach cancer that helps doctors know which patients might not respond well to chemotherapy.
Methodology
The study used endoscopic biopsy samples from gastric cancer patients to analyze gene expression before and after chemotherapy.
Potential Biases
Potential bias due to the selection of patients who were initially responsive to chemotherapy.
Limitations
The study's findings may not be generalizable to all gastric cancer patients, especially those not treated with chemotherapy.
Participant Demographics
Patients included 123 metastatic gastric cancer patients, with a median age of 58 years, and a majority were male.
Statistical Information
P-Value
0.011
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website